DrugPatentWatch Database Preview
QOLIANA Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Which patents cover Qoliana, and when can generic versions of Qoliana launch?
Qoliana is a drug marketed by Sandoz Inc and is included in one NDA. There is one patent protecting this drug.
This drug has one patent family member in one country.
The generic ingredient in QOLIANA is brimonidine tartrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.
US ANDA Litigation and Generic Entry Outlook for Qoliana
A generic version of QOLIANA was approved as brimonidine tartrate by BAUSCH AND LOMB on January 18th, 2020.
Summary for QOLIANA
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 60 |
| Patent Applications: | 40 |
| DailyMed Link: | QOLIANA at DailyMed |
Pharmacology for QOLIANA
| Drug Class | alpha-Adrenergic Agonist |
| Mechanism of Action | Adrenergic alpha-Agonists |
Synonyms for QOLIANA
| (4,5-Bihydro-1H-imidazol-2-yl)quinoxalin-6-amine L-tartrate |
| (5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate |
| 109826-56-4 |
| 359B465 |
| 4S9CL2DY2H |
| 5-bromo-N- |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine L-Tartrate |
| 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate |
| 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; (2R,3R)-2,3-dihydroxybutanedioic acid |
| 59803-98-4 (Parent) |
| 59803-99-5 |
| 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1) |
| 6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1) |
| 70359-46-5 |
| 79570-19-7 |
| A19740 |
| AB0021226 |
| AC1L1GYC |
| AC1Q59OR |
| ACT08633 |
| AGN 190342-LF |
| AGN 190342LF |
| AGN-190342-LF |
| AK-68418 |
| AKOS016845265 |
| Alphagan |
| Alphagan (TN) |
| Alphagan-P |
| AN-12800 |
| AS-18083 |
| Brimonidine (tartrate) |
| Brimonidine D-tartarate |
| Brimonidine D-tartrate |
| Brimonidine L-Tartrate |
| brimonidine Purite |
| Brimonidine tartarate |
| BRIMONIDINE TARTRATE |
| brimonidine tartrate (1:1), (S-(R*,R*))-isomer |
| Brimonidine tartrate (JAN/USAN) |
| Brimonidine tartrate [USAN:JAN] |
| Brimonidine tartrate [USAN] |
| Brimonidine tartrateUK 14,304 tartrate |
| Brimonidinne tartrate |
| Brominide tartrate |
| C11H10BrN5.C4H6O6 |
| CCG-221278 |
| CS-4496 |
| D02076 |
| EBD23481 |
| HMS3715P18 |
| HY-B0659A |
| KS-00000K6V |
| LS-177484 |
| MolPort-023-220-671 |
| N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine;(2R,3R)-2,3-dihydroxybutanedioic acid |
| SCHEMBL265607 |
| ST24046243 |
| UK 14,304 (tartrate) |
| UK-14304-18 |
| UNII-4S9CL2DY2H |
| W0014 |
US Patents and Regulatory Information for QOLIANA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | QOLIANA | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 021764-001 | May 22, 2006 | AT | RX | No | No | Start Trial | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for QOLIANA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2505836 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for QOLIANA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1631293 | 2014/041 | Ireland | Start Trial | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| 1631293 | 300683 | Netherlands | Start Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 1631293 | C300683 | Netherlands | Start Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
